CV Sciences (CVSI) Cash from Operations Growth (5y) (2016 - 2026)
CV Sciences (CVSI) Cash from Operations Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.94% |
| Mar 31, 2026 | 15.55% |
| Dec 31, 2025 | 27.21% |
| Sep 30, 2025 | 29.26% |
| Jun 30, 2025 | 16.20% |
| Mar 31, 2025 | 45.54% |
| Dec 31, 2024 | 48.72% |
| Sep 30, 2024 | 35.08% |
| Jun 30, 2024 | -15.11% |
| Mar 31, 2024 | -21.80% |
| Dec 31, 2023 | -15.36% |
| Sep 30, 2023 | -14.92% |
| Jun 30, 2023 | -17.60% |
| Mar 31, 2023 | -10.03% |
| Dec 31, 2022 | -41.12% |
| Sep 30, 2022 | -26.47% |
| Jun 30, 2022 | -53.57% |
| Mar 31, 2022 | -75.84% |
| Dec 31, 2021 | -13.26% |
| Sep 30, 2021 | -24.53% |